Nanjing Yoko Biomedical Co., Ltd.

Quick facts

Phase 3 pipeline

• Control group: Oxiracetam Injection · Neurology
  Oxiracetam enhances neuronal membrane fluidity and increases oxygen utilization in the brain, promoting cognitive function and neuroprotection.
• G-CHOP · Oncology
  G-CHOP is a chemotherapy regimen combining gemcitabine, cyclophosphamide, doxorubicin, and vincristine (Oncovin) to kill rapidly dividing cancer cells through multiple cytotoxic mechanisms.
• Ncardipine Hydrochloride Injection · Cardiovascular
  Nicardipine hydrochloride is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle cells, causing vasodilation and reducing blood pressure.
• Test group: L-oxiracetam Injection · Neurology / Cognitive disorders
  L-oxiracetam enhances neuronal membrane fluidity and facilitates neurotransmitter function, potentially improving cognitive and neurological outcomes.

Phase 1 pipeline

• GB241

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Nanjing Yoko Biomedical Co., Ltd. portfolio CI brief
• Nanjing Yoko Biomedical Co., Ltd. pipeline updates RSS